RxDoctor Payments Data

Safwat Nasrat, MD

Family Medicine · Roxboro, NCNPI 1649598830

Payments from drug & device makers

$824in general payments, 2019–2025

Across 46 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$173
  • Boehringer Ingelheim$129
  • AstraZeneca$120
  • Lilly USA, LLC$65
  • Insulet Corporation$42
  • Exact Sciences$41
  • plus $254 from 12 others

What the payments were for

  • Food & beverage$824100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$824 in reported general payments places this provider in the 65th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,317
Medicare patients
17
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$113,069
EliquisApixaban80$65,193
JardianceEmpagliflozin39$52,754
JanuviaSitagliptin Phosphate46$44,760
FarxigaDapagliflozin Propanediol56$44,395
MounjaroTirzepatide29$31,190
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$27,058
TrulicityDulaglutide11$12,099
Tresiba Flextouch U-100Insulin Degludec19$11,902
MyrbetriqMirabegron15$11,358
EntrestoSacubitril/Valsartan11$7,564
SymbicortBudesonide/Formoterol Fumarate27$7,225
Advair HfaFluticasone Propion/Salmeterol12$5,420
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$4,411
Albuterol Sulfate HfaAlbuterol Sulfate139$3,790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$173$113,06995 claims
PfizerEliquis$13$65,19380 claims
Boehringer IngelheimJardiance$129$52,75439 claims
AstraZenecaFarxiga, Symbicort$120$51,62083 claims
MerckJanuvia$28$44,76046 claims
Lilly USA, LLCMounjaro, Trulicity$65$43,28940 claims
GSKTrelegy Ellipta$25$27,05832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Roxboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →